Hims & Hers Joins Forces With Novo Nordisk
The two companies say they’re developing a roadmap that combines Novo Nordisk’s treatments with Hims & Hers’ ability to scale access to high-quality care
In a significant move to transform how Americans access weight loss treatment, telehealth platform Hims & Hers has struck a long-term partnership with pharmaceutical giant Novo Nordisk.
The news—which has prompted shares of Hims to soar—comes on the heels of new data showing that consumer spending on GLP-1 receptor agonists (RAs)—a class of drugs that includes Ozempic, Wegovy and Mounjaro—climbed from $13.7 billion in 2018 to $71.7 billion in 2023, with the sharpest growth occurring between 2022 and 2023.
The collaboration kicks off with a bundled offering that brings together all dose strengths of Novo Nordisk’s weight loss drug Wegovy with Hims & Hers’ 24/7 virtual care, clinical support, and nutrition coaching—starting this week for $599 per month through direct access to NovoCare Pharmacy via the Hims & Hers platform.
“We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications,” Hims & Hers founder and CEO Andrew Dudum said. “Bringing our teams together and continuing to explore our shared commitment and focus on delivering the future of healthcare has been inspiring. We share a vision of what consumer-centered healthcare looks like, and this is just the first step towards delivering that future.”
The telehealth platform made headlines earlier this year with its first-ever Super Bowl LIX commercial, which spotlighted that 74% of Americans are overweight and took a bold swipe at the high cost of weight loss medications—all set to Childish Gambino’s hit song “This Is America.”
“There are medications that work, but they’re priced for profits, not patients,” a narrator said during the spot. “This system wasn’t built to help us. It was built to keep us sick and stuck. But not anymore.”
According to Hims & Hers’ Shape of America report—based on a survey of 5,000 U.S. adults—the desire for weight loss has seeped into nearly every aspect of life, from household spending to personal self-worth. Weight remains top of mind for consumers, with 75% of Americans thinking about their weight daily and 14% admitting it’s a constant concern, highlighting the demand for solutions.
“We are pleased that Hims & Hers is making this offering available this week to people living with obesity,” said Dave Moore, Novo Nordisk executive vice president, U.S. operations and global business development and president. “Beyond this initial collaboration, the companies are developing a roadmap that combines Novo Nordisk’s innovative medications with Hims & Hers’ ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably.”
Earlier this year, Hims & Hers acquired Trybe Labs (also known as Sigmund NJ LLC), a New Jersey-based at-home lab testing facility to support its plans to enter new areas, including low testosterone treatment and perimenopausal and menopausal support. It then swiftly announced the acquisition of a U.S.-based peptide facility in California—an investment meant to advance its personalized treatment plans.